DrugPatentWatch Database Preview
Patent: 9,963,507
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Summary for Patent: 9,963,507
| Title: | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis |
| Abstract: | Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-B cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention. In other embodiments, optimal dosages of therapeutic antibody may be selected by monitoring the degree of trogocytosis induced by anti-B cell antibodies. Other characteristics of anti-B-cell antibodies that may be monitored include inducing phosphorylation of CD22, CD79a and CD79b; inducing translocation of CD22, CD79a and CD79b to lipid rafts; inducing caspase-dependent apoptosis; increasing pLyn, pERKs and pJNKs; decreasing constitutively-active p38; or inducing mitochondrial membrane depolarization, generation of reactive oxygen species, upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-xl, Mcl-1 and Bcl-2. |
| Inventor(s): | Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), Hansen; Hans J. (Diamondhead, MS), Rossi; Edmund A. (Woodland Park, NJ) |
| Assignee: | Immunomedics, Inc. (Morris Plains, NJ) |
| Application Number: | 15/492,752 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,963,507
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | ELSPAR | asparaginase | VIAL | 101063 | 001 | 1978-01-10 | Start Trial | Immunomedics, Inc. (Morris Plains, NJ) | 2031-12-05 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,963,507
| Country | Patent Number | Publication Date |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013085893 | Jun 13, 2013 |
| World Intellectual Property Organization (WIPO) | 2013181087 | Dec 05, 2013 |
| World Intellectual Property Organization (WIPO) | 2013181087 | Feb 06, 2014 |
| United States of America | 2013142787 | Jun 06, 2013 |
| United States of America | 2013323204 | Dec 05, 2013 |
| >Country | >Patent Number | >Publication Date |
